Following these proceedings, Cantor Fitzgerald initiated its SELLAS Life Sciences Group Inc [SLS] rating to an Overweight in a research note published on July 21, 2021; the price target was $18. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early November with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering SLS with “Buy” recommendation on April 02, 2018. Maxim Group revised its rating on March 19, 2018. It rated SLS as “a Buy” which previously was an “a Hold”.
Price Performance Review of SLS
On Monday, SELLAS Life Sciences Group Inc [NASDAQ:SLS] saw its stock fall -1.28% to $1.54. Over the last five days, the stock has lost -9.94%. SELLAS Life Sciences Group Inc shares have risen nearly 48.08% since the year began. Nevertheless, the stocks have risen 20.31% over the past one year. While a 52-week high of $1.85 was reached on 05/05/25, a 52-week low of $0.77 was recorded on 01/23/25. SMA at 50 days reached $1.2734, while 200 days put it at $1.2101.
Levels Of Support And Resistance For SLS Stock
The 24-hour chart illustrates a support level at 1.4767, which if violated will result in even more drops to 1.4133. On the upside, there is a resistance level at 1.6217. A further resistance level may holdings at 1.7033. The Relative Strength Index (RSI) on the 14-day chart is 59.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0419, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.36%. Stochastics %K at 55.34% indicates the stock is a holding.
